MX2024005899A - Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos. - Google Patents

Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.

Info

Publication number
MX2024005899A
MX2024005899A MX2024005899A MX2024005899A MX2024005899A MX 2024005899 A MX2024005899 A MX 2024005899A MX 2024005899 A MX2024005899 A MX 2024005899A MX 2024005899 A MX2024005899 A MX 2024005899A MX 2024005899 A MX2024005899 A MX 2024005899A
Authority
MX
Mexico
Prior art keywords
masp
inhibitory agent
disease
compositions
subject
Prior art date
Application number
MX2024005899A
Other languages
English (en)
Inventor
Patrick Gray
Gregory A Demopulos
Hans-Wilhelm Schwaeble
Thomas Dudler
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49769678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2024005899(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2024005899A publication Critical patent/MX2024005899A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)

Abstract

En un aspecto, la invención proporciona métodos y composiciones para inhibir la activación del complemento dependiente de MASP-3 en un sujeto sujeto que padece de, o está en riesgo de desarrollar, una enfermedad o trastorno seleccionado del grupo que consiste de degeneración macular relacionada con la edad, artritis, coagulación intravascular diseminada, microangiopatía trombótica, asma, enfermedad de depósitos densos, glomerulonefritis crescéntica necrotizante y pauci-inmune, lesión cerebral traumática, neumonía por aspiración, endoftalmitis, neuromielitis óptica y enfermedad de Behcet al administrar al sujeto una composición que comprende una cantidad de un agente inhibidor de MASP-3 en una cantidad eficaz para inhibir la activación del complemento dependiente de MASP-3. En algunas modalidades, al sujeto se le administra un agente inhibidor de MASP-2 y un agente inhibidor de MASP-1, un agente inhibidor de MASP-2 y un agente inhibidor de MASP-3, un agente inhibidor de MASP-3 y un agente inhibidor de MASP-1, o un agente inhibidor de MASP-1, un agente inhibidor de MASP-2 y un agente inhibidor de MASP-3.
MX2024005899A 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos. MX2024005899A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661167P 2012-06-18 2012-06-18

Publications (1)

Publication Number Publication Date
MX2024005899A true MX2024005899A (es) 2024-05-30

Family

ID=49769678

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014015715A MX2014015715A (es) 2012-06-18 2013-06-18 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2024005899A MX2024005899A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2020005700A MX2020005700A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2019012909A MX2019012909A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014015715A MX2014015715A (es) 2012-06-18 2013-06-18 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020005700A MX2020005700A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2019012909A MX2019012909A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.

Country Status (27)

Country Link
US (4) US20130344073A1 (es)
EP (4) EP4119577A3 (es)
JP (5) JP6445972B2 (es)
KR (4) KR102339315B1 (es)
CN (3) CN115040653A (es)
AU (3) AU2013277309B2 (es)
BR (1) BR112014031522A2 (es)
CA (2) CA2875567C (es)
CL (2) CL2014003455A1 (es)
CY (1) CY1124234T1 (es)
DK (1) DK2861246T3 (es)
ES (1) ES2864857T3 (es)
HK (1) HK1209623A1 (es)
HR (1) HRP20210559T1 (es)
HU (1) HUE053727T2 (es)
IL (2) IL236327B (es)
IN (1) IN2015KN00015A (es)
LT (1) LT2861246T (es)
MX (4) MX2014015715A (es)
NZ (1) NZ629473A (es)
PL (1) PL2861246T3 (es)
PT (1) PT2861246T (es)
RS (1) RS61755B1 (es)
RU (2) RU2709351C2 (es)
SI (1) SI2861246T1 (es)
WO (1) WO2013192240A2 (es)
ZA (1) ZA201500094B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CN103781492A (zh) 2011-04-08 2014-05-07 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的状况的方法
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
US9217042B2 (en) * 2012-10-23 2015-12-22 Abbott Cardiovascular Systems Inc. Method of reducing MACE in diabetic patients subsequent to stent placement
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
JP2016514456A (ja) 2013-03-15 2016-05-23 オメロス コーポレーション 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
EP2983710B1 (en) * 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
WO2014197885A2 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
JP6462680B2 (ja) 2013-07-09 2019-01-30 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
ES2829913T3 (es) 2013-10-17 2021-06-02 Omeros Corp Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
EP3151845A4 (en) * 2014-06-05 2018-01-17 The Regents of the University of Colorado, a body corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
CN107207587B (zh) 2014-11-05 2022-04-19 安尼艾克松股份有限公司 人源化抗-补体因子c1q抗体及其应用
WO2016186994A1 (en) * 2015-05-15 2016-11-24 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of thrombotic microangiopathy
WO2016196902A1 (en) * 2015-06-03 2016-12-08 Coyne Ip Holdings, Llc Methods for establishing threshold limits for a chemical or biological agent in a target species
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
UA124094C2 (uk) 2015-11-09 2021-07-21 Омерос Корпорейшн Спосіб лікування стану, пов'язаного з masp-2-залежною активацією комплементу
US10723788B2 (en) 2015-11-24 2020-07-28 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
EP3400012A4 (en) * 2016-01-05 2019-12-11 University Of Leicester PROCESS FOR INHIBITING FIBROSIS IN A NEEDED SUBJECT
CN115137816A (zh) * 2016-03-31 2022-10-04 奥默罗斯公司 抑制有需要的受试者的血管发生的方法
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
ES2933513T3 (es) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Compuestos macrocíclicos para el tratamiento de trastornos médicos
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2018186322A1 (en) * 2017-04-03 2018-10-11 Chugai Seiyaku Kabushiki Kaisha Anti-masp-1 antibodies and methods of use
MX2020002077A (es) * 2017-08-25 2020-03-24 Omeros Corp Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentradas, kits y metodos para el tratamiento de sujetos que padecen sindrome hemolitico atipico.
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
MX2020010528A (es) * 2018-04-13 2020-11-06 Chugai Pharmaceutical Co Ltd Anticuerpos anti-componente de complemento y metodos de uso.
US20200140570A1 (en) * 2018-06-22 2020-05-07 Omeros Corporation Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
CA3111810A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of dancopan
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
MX2021013616A (es) * 2019-05-07 2021-12-10 Bayer Ag Compuestos inhibidores de la masp y usos de estos.
US12030853B2 (en) 2019-12-04 2024-07-09 Omeros Corporation MASP-2 inhibitors and methods of use
WO2021113686A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
CA3159167A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
CN112237630A (zh) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用
TW202319069A (zh) * 2020-03-06 2023-05-16 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CN115215937B (zh) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
IL313331A (en) 2021-12-10 2024-08-01 Omeros Corp Therapeutic antibodies that bind to the SERINE PROTEASE domain of MASP-2 and uses thereof
CN114989259B (zh) * 2022-05-27 2023-06-09 成都佩德生物医药有限公司 一种小分子肽Ped4及应用
US20240228499A1 (en) 2022-11-30 2024-07-11 Omeros Corporation Masp-2 inhibitors and methods of use
WO2024186766A1 (en) * 2023-03-03 2024-09-12 The City University Of New York Use of extracellular vesicles as biomarkers for age-related macular degeneration

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
CA2391402A1 (en) * 1999-12-02 2001-06-07 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
CN1652813A (zh) * 2002-03-15 2005-08-10 纳蒂芒公司 包含甘露糖结合凝集素的药用组合物
ES2601143T3 (es) 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
DE602004031836D1 (de) * 2003-07-08 2011-04-28 Umc Utrecht Holding Bv Therapeutische verwendung von lpi, einem inhibitor des lectinwegs in staphylokokken bei entzündungskrankheiten
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA3102252A1 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN100518905C (zh) * 2004-11-02 2009-07-29 浙江欧美环境工程有限公司 折返式电除盐器
MY169746A (en) 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007047995A2 (en) * 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
SI2596807T1 (sl) * 2006-03-08 2016-03-31 Archemix Llc Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj
JP5537420B2 (ja) 2007-05-31 2014-07-02 ユニヴァーシティ オブ ワシントン 標的遺伝子の誘導性変異誘発
EP3121197A1 (en) * 2008-11-10 2017-01-25 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CA2766565A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2011006982A2 (en) * 2009-07-17 2011-01-20 Rigshospitalet Inhibitors of complement activation
BR112012008970A2 (pt) * 2009-10-16 2019-12-10 Omeros Corp uso de uma composição, e, composição
CA2791841C (en) * 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
CN103781492A (zh) * 2011-04-08 2014-05-07 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的状况的方法
RU2018114903A (ru) * 2012-04-06 2019-03-04 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии

Also Published As

Publication number Publication date
IL236327B (en) 2019-02-28
EP3878865A2 (en) 2021-09-15
US20240254257A1 (en) 2024-08-01
CL2016003297A1 (es) 2017-06-02
JP6771531B2 (ja) 2020-10-21
SI2861246T1 (sl) 2021-08-31
ES2864857T3 (es) 2021-10-14
JP2024099699A (ja) 2024-07-25
JP2015521623A (ja) 2015-07-30
HRP20210559T1 (hr) 2021-05-14
RU2019140356A (ru) 2020-01-27
JP2022084946A (ja) 2022-06-07
MX2020005700A (es) 2020-09-25
PL2861246T3 (pl) 2021-10-25
JP6445972B2 (ja) 2018-12-26
NZ728179A (en) 2021-12-24
AU2013277309A1 (en) 2015-01-22
CA2875567A1 (en) 2013-12-27
JP2021006546A (ja) 2021-01-21
LT2861246T (lt) 2021-04-26
US20130344073A1 (en) 2013-12-26
IL261436B (en) 2021-08-31
EP3058951A1 (en) 2016-08-24
HK1209623A1 (en) 2016-04-08
IL261436A (en) 2018-11-04
ZA201500094B (en) 2019-08-28
HUE053727T2 (hu) 2021-07-28
CN115040653A (zh) 2022-09-13
KR20150031298A (ko) 2015-03-23
CY1124234T1 (el) 2022-05-27
MX2014015715A (es) 2016-02-05
AU2018204285B2 (en) 2020-02-27
CN109908352A (zh) 2019-06-21
IN2015KN00015A (es) 2015-07-31
KR20200116164A (ko) 2020-10-08
KR20220100997A (ko) 2022-07-18
MX2019012909A (es) 2020-12-10
IL236327A0 (en) 2015-02-26
CN104717975A (zh) 2015-06-17
PT2861246T (pt) 2021-04-05
JP2019048881A (ja) 2019-03-28
EP4119577A2 (en) 2023-01-18
US20220259325A1 (en) 2022-08-18
RU2015101230A (ru) 2016-08-10
EP2861246B1 (en) 2021-01-20
WO2013192240A3 (en) 2014-07-03
EP4119577A3 (en) 2023-11-08
DK2861246T3 (en) 2021-04-26
BR112014031522A2 (pt) 2017-08-01
US20190127484A1 (en) 2019-05-02
CA3214532A1 (en) 2013-12-27
NZ629473A (en) 2017-02-24
WO2013192240A2 (en) 2013-12-27
EP2861246A2 (en) 2015-04-22
AU2020202999A1 (en) 2020-05-28
AU2020202999B2 (en) 2022-03-24
EP2861246A4 (en) 2016-03-23
KR20200015952A (ko) 2020-02-13
RS61755B1 (sr) 2021-05-31
RU2709351C2 (ru) 2019-12-17
CA2875567C (en) 2023-11-14
KR102339315B1 (ko) 2021-12-15
AU2013277309B2 (en) 2018-03-29
EP3878865A3 (en) 2021-12-08
CL2014003455A1 (es) 2015-04-10

Similar Documents

Publication Publication Date Title
MX2024005899A (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MX356865B (es) Nuevas soluciones terapéuticas para tratar la enfermedad de parkinson.
WO2013061161A3 (en) New combination therapies for treating neurological disorders
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
NZ629675A (en) Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY173699A (en) Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
MX2015007479A (es) Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas.
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
WO2016090024A3 (en) Combination therapy for treatment of cancer
EP4124346A3 (en) Compositions and methods for treating diseases
MX2015004389A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionadods.
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
MX2021006985A (es) Metodos para el tratamiento de la depresión.
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
MX2021000515A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
MX343366B (es) Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica.
MX342459B (es) 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3.
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
EA201991460A1 (ru) Антисмысловые олигонуклеотиды для лечения болезни штаргардта